Evidence map›Paper›PMID 32298430›Full record

ArticleBlood advances2020

American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

M R DeBaun, L C Jordan, A A King, J Schatz, E Vichinsky, C K Fox, R C McKinstry, P Telfer, M A Kraut, L Daraz and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06562439 (Early Identification and Intervention Of Developmental Delay Among Infants And Toddlers With Sickle Cell Disease Using the Sickle Cell Caregiver Collaboration for Child Development), which is not on this map. Cited by 201 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed, 5 pooled it
27.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06562439 nawithdrawnnot on this mapstarted 2025, after this paper: background citation

Early Identification and Intervention Of Developmental Delay Among Infants And Toddlers With Sickle Cell Disease Using the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention

TypeinterventionalSponsorWashington University School of MedicineRan2025 to 2028Enrolled0ConditionsSickle Cell DiseaseArmsSickle Cell Collaboration for Child Development
3 · Its place in the literature

Who cites it

201 citing papers in PubMed, 5 syntheses or guidelines pooled it, 392 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

141 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

M R DeBaunDepartment of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, and.
L C JordanDivision of Pediatric Neurology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
A A KingProgram in Occupational Therapy, Division of Hematology, Department of Pediatrics/Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
J SchatzDepartment of Psychology, University of South Carolina, Columbia, SC.
E VichinskyChildren's Hospital Oakland Research Institute, Oakland, CA.
C K FoxDepartment of Neurology and.
R C McKinstryDepartment of Radiology and.
P TelferCentre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London, United Kingdom.
M A KrautDepartment of Radiology, School of Medicine, Johns Hopkins University, Baltimore, MD.
L DarazEvidence-Based Practice Center, Mayo Clinic, Rochester, MN.
F J KirkhamDevelopmental Neurosciences Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
M H MuradEvidence-Based Practice Center, Mayo Clinic, Rochester, MN.
Mayo Clinic · USWashington University in St. Louis · USGreat Ormond Street Hospital · GBJohns Hopkins University · USQueen Mary University of London · GBUniversity of California, San Francisco · USUniversity of South Carolina · USVanderbilt University Medical Center · US

Funding

Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
6 · The paper itself

Abstract

backgroundCentral nervous system (CNS) complications are among the most common, devastating sequelae of sickle cell disease (SCD) occurring throughout the lifespan.

objectiveThese evidence-based guidelines of the American Society of Hematology are intended to support the SCD community in decisions about prevention, diagnosis, and treatment of the most common neurological morbidities in SCD.

methodsThe Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic evidence reviews. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations.

resultsThe panel placed a higher value on maintaining cognitive function than on being alive with significantly less than baseline cognitive function. The panel developed 19 recommendations with evidence-based strategies to prevent, diagnose, and treat CNS complications of SCD in low-middle- and high-income settings.

conclusionsThree of 19 recommendations immediately impact clinical care. These recommendations include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in children with hemoglobin SS (HbSS) and hemoglobin Sβ0 (HbSβ0) thalassemia living in low-middle-income settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral infarcts at least once in early-school-age children and once in adults with HbSS or HbSβ0 thalassemia. Individuals with SCD, their family members, and clinicians should become aware of and implement these recommendations to reduce the burden of CNS complications in children and adults with SCD.

Indexed as

Anemia, Sickle CellHematologyStrokeAdultChildHemoglobin, SickleHumansHydroxyureaUnited StatesHemoglobin, SickleHydroxyureaAnemia-Clinical: Sickle cell anemiaRED CELLS

Identifiers

PMID32298430
PMCPMC7189278
OpenAlexW3016914388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.